KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs

Pancreatic ductal adenocarcinoma (PDAC) is a dominantly (~95%) KRAS-mutant cancer that has extremely poor prognosis, in part this is due to its strong intrinsic resistance towards almost all therapeutic agents. PDAC relies heavily on KRAS-transformed metabolism, including enhanced macropinocytosis a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2019-02, Vol.296, p.40-53
Hauptverfasser:	Liu, Huiqin, Sun, Mengnan, Liu, Zhengsheng, Kong, Chao, Kong, Weijian, Ye, Junxiao, Gong, Jianan, Huang, David C.S., Qian, Feng
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin conjugated drug Albumins - administration & dosage Animals Antibiotics, Antineoplastic - administration & dosage Cell Line, Tumor Doxorubicin - administration & dosage FcRn Histocompatibility Antigens Class I - genetics Human Umbilical Vein Endothelial Cells Humans KRAS Macropinocytosis Male Mice, Inbred BALB C Mice, Nude Pancreatic cancer Pancreatic Neoplasms - drug therapy Pinocytosis Proto-Oncogene Proteins p21(ras) - genetics Receptors, Fc - genetics RNA, Small Interfering - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!